CliffBio
small molecule

LIFYORLI (COPACKAGED)

RELACORILANT

Loss of exclusivityDecember 2041latest FDA-listed patent expiry
CompanyCorcept Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameLIFYORLI (COPACKAGED)
Active ingredientRELACORILANT
Strength100MG;25MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2026
Marketing statusRX

Listed patents

PatentExpiresType
12152028December 2041product
11285145May 2041use U-4459
12589094May 2041use U-4459
11464764April 2040product
12514849December 2039product
11925626December 2039product
9273047May 2033use U-4459
10456392May 2033use U-4457
8859774May 2033substance, product
11576907May 2033substance, product

Regulatory exclusivity

CodeExpires
NCEMarch 2031

More from Corcept Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LIFYORLI (COPACKAGED) patent cliff — loss of exclusivity December 2041 | CliffBio